Pharmacomicrobiomics: Deciphering the Bidirectional Interplay between Gut Microbiota and Pharmaceuticals for Optimized Therapy

Introduction: The intestinal mucosa microbiota plays an important role in drug metabolism, which impacts pharmacodynamics and pharmacokinetics. This review examines the two-way interactions between gut microbes and drugs, with an emphasis on their influence on drug efficacy, drug toxicity, and individualized drug responses. Methods: A thorough literature review was performed in PubMed, Web of Science, Scopus, and Google Scholar with the help of the keywords associated with gut microbiota and drug metabolism. The period of inclusion was 2000-2025, and the forerunners considered were original research, reviews, and meta-analyses. Data extraction and synthesis were conducted to summarize the key findings. Results: The main conclusions are that the gut microbiota can activate prodrugs, modify drug bioavailability, and mediate microbial transformations via enzymes. In addition, pharmaceuticals may affect gut microbiota and result in dysbiosis. Promising microbiome- driven interventions to improve drug reactions, reduce toxicity, and mitigate adverse effects include probiotics, prebiotics, synbiotics, and fecal microbiota transplantation. Discussion: Personalized medicine can have significant implications because the gut microbiota dynamically interacts with pharmacology. Knowledge of these interactions could be used to improve therapeutic outcomes, as it may be applied to accommodate individual differences in drug reactions associated with microbial makeup. Conclusion: The gut microbiota is a very important regulator of drug metabolism and thus a determining factor in individualized medicine. Future studies must aim to use microbiome science to develop novel curative models that maximize drug effects and minimize toxicity.